Polimorfismos genéticos y alteraciones clínicas presentes en pacientes con anemia de Fanconi
Resumen
La anemia de Fanconi es una enfermedad hereditaria con una incidencia mundial baja, con variedad genotípica asociada a alteraciones hematológicas y procesos neoplásicos, lo que la convierte en una enfermedad con un mal pronóstico y una tasa de supervivencia baja, si no es detectada a tiempo. Actualmente la variable más común de la enfermedad es la anemia de Fanconi tipo A, que posee manifestaciones clínicas como microcefalia, fístula traqueoesofágica o microftalmia, estando presente en más de la mitad de los pacientes con anemia de Fanconi. El diagnóstico de esta se basa en las manifestaciones clínicas y se confirma mediante pruebas de fragilidad cromosómica, lo que facilita la conducta a tomar por el personal médico para dar un tratamiento oportuno. Lo que se desarrollará a lo largo de la lectura son el método diagnóstico, tratamiento y alteraciones genotípicas y fenotípicas de la anemia de Fanconi.
Descargas
Citas
Borges M, Souza J, Rodrigues L, Cornélio M, Anjos A, Santos N, et al. Clinical and cytogenetic profile of Fanconi anemia diagnosed after implementation of mitomycin C cytogenetic test in the state of Pernambuco, Brazil. Hematol Transfus Cell Ther. 2023; S2531-1379(23)00001-9. DOI: 10.1016/j.htct.2022.11.011.
Altintas B, Giri N, McReynolds LJ, Best A, Alter BP. Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. Haematologica. 2023; 108(1):69-82. DOI: 10.3324/haematol.2021.279981
Lyakhovich A, Surralles J. New Roads to FA/BRCA Pathway: H2AX.Cell Cycle. 2007; 6(9):1019-1023. DOI: 10.4161/cc.6.9.4223
Rego MA, Harney JA, Mauro M, Shen M, Howlett NG. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene. 2012; 31(3):366-75. DOI: 10.1038/onc.2011.237.
Auerbach A. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol. 1993; 21(6):731-3.
Castella M, Pujol R, Callén E, Trujillo JP, Casado J, Gille H, et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood. 2011; 117(14):3759-69. DOI: 10.1182/blood-2010-08-299917.
Joenje H, Patel K. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001; 2(6):446-457.
Kennedy R, D’Andrea A. The Fanconi anemia/ BRCA pathway: new faces in the crowd. Genes Dev. 2005; 19(24):2925-2940.
Callén E, Casado JA, Tischkowitz MD, Bueren JA, Creus A, Marcos R, et al. A common founder mutation in FANCA underlies the world’s highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood. 2005; 105(5):1946-9. DOI: 10.1182/blood-2004-07-2588.
Whitney MA, Saito H, Jakobs PM, Gibson RA, Moses RE, Grompe M. A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. Nat Genet. 1993; 4(2):202-5. DOI: 10.1038/ng0693-202.
Tipping A, Pearson T, Morgan N, Gibson R, Kuyt L, Havenga C, et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci U S A. 2001; 98(10):5734-9. DOI: 10.1073/pnas.091402398.
Rosenberg P, Tamary H, Alter B. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet. 2011; 155:1877–83.
Caputo LZ. Implantacao da tecnica de quebras cromossomicas com Diepoxibutano (DEB) em laboratorio de citogenetica: um estudo de 148 casos [thesis], Sao Paulo: Universidade de Sao Paulo; 2002. p. 111
Rodriguez DEA, Lima CSP, Lourenco GJ, Figueiredo ME, Carneiro JDA, Tone LG, et al. Molecular analysis of the most prev- alent mutations of the FANCA and FANCC genes in Brazilian patients with Fanconi anaemia. Genet Mol Biol. 2005; 28:205–9.
Pilonetto DV, Pereira NF, Bonfim CMS, Ribeiro LL, Bitencourt MA, Kerkhoven L, et al. A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients. Mol Genet Genomic Med. 2017; 5:360–72.
Mehta PA, Ebens C. Fanconi Anemia. 2002 Feb 14 [Updated 2021 Jun 3]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.
Fink O, Even-Or E, Avni B, Grisariu S, Zaidman I, Schejter Y, et al. Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes. Clin Transplant. 2023; 37(1): e14835. DOI: 10.1111/ctr.14835.
Zhou Z, Yin H, Suye S, He J, Fu C. Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E. Front Genet. 2023; 13:1024989. DOI: 10.3389/fgene.2022.1024989.
Verhagen C, Vossen D, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M. Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget. 2018; 9(26):18198-213. DOI: 10.18632/oncotarget.24797.
Xu H, Xiong C, Chen Y, Zhang C, Bai D. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered. 2021; 12(1):2664-75. DOI: 10.1080/21655979.2021.1938470.
Miao H, Ren Q, Li H, Zeng M, Chen D, Xu C, Chen Y, et al. Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma. BMC Cancer. 2022; 22(1):225. DOI: 10.1186/s12885-022-09314-9.
Fagerholm R, Sprott K, Heikkinen T, Bartkova J, Heikkilä P, Aittomäki L. Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Ann Oncol. 2013; 24(11):2780-5. DOI: 10.1093/annonc/mdt290.
Liu X, Liu X, Han X. FANCI may serve as a prognostic biomarker for cervical cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(51): e27690. DOI: 10.1097/
Ding J, Wang G, Shi W, Zhou H, Zhao E. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer. Reprod Sci. 2016; 23(1):24-30. DOI: 10.1177/
Fiesco-Roa MO, Giri N, McReynolds LJ, Best AF, Alter BP. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Rev. 2019; 37:100589. DOI: 10.1016/j.blre.2019.100589.
Solomon BD, Baker LA, Bear KA, Cunningham BK, Giampietro PF, Hadigan C, et al. An approach to the identification of anomalies and etiologies in neonates with identified or suspected VACTERL (vertebral defects, anal atresia, tracheo-esophageal fistula with esophageal atresia, cardiac anomalies, renal anomalies, and limb anomalies) association. J Pediatr.2014; 164(3): 451-7.e1.DOI: 10.1016/j.jpeds.2013.10.086.
Alter BP, Giri N. Thinking of VACTERL-H? Rule out Fanconi Anemia according to PHENOS. Am J Med Genet A. 2016; 170(6):1520-4. DOI: 10.1002/ajmg.a.37637.
Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014; 27(3-4):214-21. DOI: 10.1016/j.beha.2014.10.002.
Rose SR, Myers KC, Rutter MM, Mueller R, Khoury JC, Mehta PA, et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012;59(4):690-6. DOI: 10.1002/pbc.24095.
Källén K, Mastroiacovo P, Castilla EE, Robert E, Källén B. VATER non-random association of congenital malformations: study based on data from four malformation registers. Am J Med Genet. 2001; 101(1):26-32. DOI: 10.1002/ajmg.1201.
Rosenberg PS, Huang Y, Alter BP. Individualized risks of first adverse events in patients with Fanconi anemia. Blood. 2004; 104(2):350-5. DOI: 10.1182/blood-2004-01-0083.
Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010; 24(3):101-22. DOI: 10.1016/j.blre.2010.03.002.
Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 103(1):30-39. DOI: 10.3324/haematol.2017.178111.
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003; 101(4):1249-56. DOI: 10.1182/blood-2002-07-2170.
Tönnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood. 2003; 101(10):3872-4. DOI: 10.1182/blood-2002-10-3243.
Rochowski A, Olson SB, Alonzo TA, Gerbing RB, Lange BJ, Alter BP. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatr Blood Cancer. 2012; 59(5):922-4. DOI: 10.1002/pbc.24168.
Chao MM, Thomay K, Goehring G, Wlodarski M, Pastor V, Schlegelberger B, et al. Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms. Klin Padiatr. 2017; 229(6):329-334. English. DOI: 10.1055/s-0043-117046.
Magdalena N, Pilonetto DV, Bitencourt MA, Pereira NF, Ribeiro RC, Jeng M, et al. Frequency of Fanconi anemia in Brazil and efficacy of screening for the FANCA 3788-3790del mutation. Braz J Med Biol Res. 2005; 38(5):669-73. DOI: 10.1590/s0100-879x2005000500003.
Moreno OM, Sánchez AI, Herreño A, Giraldo G, Suárez F, Prieto JC, et al. Phenotypic Characteristics and Copy Number Variants in a Cohort of Colombian Patients with VACTERL Association. Mol Syndromol. 2020; 11(5-6):271-283. DOI: 10.1159/000510910.
Gluckman E, Devergie A, Schaison G, Bussel A, Berger R, Sohier J, et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol. 1980; 45(4):557-64. DOI: 10.1111/j.1365-2141.1980.tb07178.
Oostra AB, Nieuwint AW, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia. 2012; 2012:238731. DOI: 10.1155/2012/238731.
Auerbach AD. Diagnosis of Fanconi anemia by diepoxybutane analysis. Curr Protoc Hum Genet. 2015; 85:8.7.1-8.7.17. DOI: 10.1002/0471142905.hg0807s85.
Castella M, Pujol R, Callén E, Ramírez MJ, Casado JA, Talavera M, et al. Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. J Med Genet. 2011; 48(4):242-50. DOI: 10.1136/jmg.2010.084210.
Fargo JH, Rochowski A, Giri N, Savage SA, Olson SB, Alter BP. Comparison of chromosome breakage in non-mosaic and mosaic patients with Fanconi anemia, relatives, and patients with other inherited bone marrow failure syndromes. Cytogenet Genome Res. 2014; 144(1):15-27. DOI: 10.1159/000366251.
Flynn EK, Kamat A, Lach FP, Donovan FX, Kimble DC, Narisu N, et al. Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes. Hum Mutat. 2014; 35(11):1342-53. DOI: 10.1002/humu.22680.
Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodriguez-Santiago B, et al. Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. J Med Genet. 2020; 57(4):258-268. DOI: 10.1136/jmedgenet-2019-106249.
de Jong EM, Felix JF, de Klein A, Tibboel D. Etiology of esophageal atresia and tracheoesophageal fistula: “mind the gap”. Curr Gastroenterol Rep. 2010; 12(3):215-22. DOI: 10.1007/s11894-010-0108-1.
Beauregard-Lacroix E, Tardif J, Lemyre E, Kibar Z, Faure C, Campeau PM. Genetic Testing in a Cohort of Complex Esophageal Atresia. Mol Syndromol. 2017; 8(5):236-243. DOI: 10.1159/000477429.
Wegman-Ostrosky T, Savage SA. The genomics of inherited bone marrow failure: from mechanism to the clinic. Br J Haematol. 2017;177(4):526-542. DOI: 10.1111/bjh.14535.
Solomon BD. VACTERL/VATER Association. Orphanet J Rare Dis. 2011; 6:56. DOI: 10.1186/1750-1172-6-56.
Van Maldergem L, Piard J, Larizza L, Wang LL. Baller-Gerold Syndrome. 2007 Aug 13 [updated 2018 Apr 19]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
Kallen ME, Dulau-Florea A, Wang W, Calvo KR. Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. Semin Hematol. 2019 Jan;56(1):69-82. DOI: 10.1053/j.seminhematol.2018.05.016.
Murillo-Sanjuán L, González-Vicent M, Argilés Aparicio B, Badell Serra I, Rodríguez Villa A, Uria Oficialdegui ML, et al. Survival and toxicity outcomes of hematopoietic stem cell transplantation for pediatric patients with Fanconi anemia: a unified multicentric national study from the Spanish Working Group for Bone Marrow Transplantation in Children. Bone Marrow Transplant. 2021; 56(5):1213-1216. DOI: 10.1038/s41409-020-01172-y.
Dufour C, Pierri F. Modern management of Fanconi anemia. Hematology Am Soc Hematol Educ Program. 2022; 2022(1):649-657. DOI: 10.1182/hematology.2022000393.
Calado RT, Clé DV. Treatment of inherited bone marrow failure syndromes beyond transplantation. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):96-101. DOI: 10.1182/asheducation-2017.1.96.
Pollard JA, Furutani E, Liu S, Esrick E, Cohen LE, Bledsoe J, et al. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Adv. 2022; 6(12):3803-3811. DOI: 10.1182/bloodadvances.2021006490.
Sevilla J, Navarro S, Rio P, Sánchez-Domínguez R, Zubicaray J, Gálvez E, et al. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Mol Ther Methods Clin Dev. 2021; 22:66-75. DOI: 10.1016/j.omtm.2021.06.001.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Santiago Ramirez-Arango
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
